Clinical Trials Logo

Abatacept clinical trials

View clinical trials related to Abatacept.

Filter by:
  • None
  • Page 1

NCT ID: NCT05451615 Recruiting - Clinical trials for Rheumatoid Arthritis

Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

Start date: September 30, 2022
Phase: Phase 3
Study type: Interventional

The aim of this study is to observe the clinical efficacy and safety of abatacept combined with JAK inhibitor in the treatment of D2TRA patients

NCT ID: NCT04946669 Recruiting - Dermatomyositis Clinical Trials

An Exploratory Study on the Efficacy and Safety of Abatacept in the Treatment of Refractory Dermatomyositis

Start date: February 1, 2021
Phase: Early Phase 1
Study type: Interventional

Dermatomyositis is a heterogeneous disease characterized by involvement of the proximal muscles of the extremities. Some patients have treatment failure or intolerance to the above treatment regimens, which is called refractory dermatomyositis. Abatacept has been approved by the FDA for the treatment of three types of rheumatoid immune diseases, and the international consensus of experts recommends abacepil as a second-line regimen for the treatment of refractory dermatomyositis based on the evidence of case reports.

NCT ID: NCT04686929 Recruiting - Prevention Clinical Trials

Abatacept s.c. for aGVHD Prevention in Haplo-HCT

Start date: June 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Acute graft-versus-host disease (aGVHD) is a potentially fatal complication after allogeneic hematopoietic cell transplantation (HCT), particularly for that with a HLA-mismatched donor. Abatacept has been demonstrated as a potent drug to reduce the risk of aGVHD, but the efficacy of subcutaneous form has yet been investigated. This trial is designed to preliminarily determin the efficacy and saftey of subcutaneous abatacept in the prevention of aGVHD after haplo-identical HCT.